US FDA adds new warning on Johnson & Johnson COVID-19 vaccine related to rare neurological disorder called Guillain-Barre syndrome

The US Food and Drug Administration (FDA) added a new warning on the Johnson & Johnson Covid-19 vaccine, saying the jab has been linked to a serious but rare side effect called Guillain-Barre syndrome.

Guillain Barre syndrome is a neurological disorder in which the body's immune system damages nerve cells, causing muscle weakness and sometimes paralysis, Xinhua news agency reported citing the FDA as saying.

The syndrome has occurred in some people who have received the Johnson & Johnson vaccine, the FDA in a letter on Monday.

In most of these people, symptoms began within 42 days following injections of the vaccine, it added.

The chance of having this occur is very low, the agency said.

About 100 preliminary reports of Guillain-Barre syndrome have been detected in vaccine recipients after the administration of 12.8 million doses of the Johnson & Johnson jab in the US, The Washington Post quoted the Centers for Disease Control and Prevention (CDC) as saying in a statement.

Of these reports, 95 were serious and required hospitalization, and one had dead.

The cases have largely been reported about two weeks after vaccination and mostly in men, many aged 50 and older, according to the CDC.

Johnson & Johnson said on Monday it has been in discussions with the FDA and other regulators about rare cases of Guillain-Barre syndrome.

The chance of having this occur is very low, and the rate of reported cases exceeds the background rate by a small degree, the company said in a statement.


SEE ALSO:
Paytm Money now allows investors to apply for an IPO before opening, Zomato being the first
Nirvaan Birla’s edtech startup Birla Brainiacs plans to raise up to $10 million, to hire 1500 teachers in the next two years
Amazon India product pages are down across the website as buyers begin their Monday morning shopping